Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia

Alberto A Antunes; Miguel Srougi; Rafael F Coelho; Geraldo de Campos Freire

doi:10.1038/ncpuro0735

Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia

Nat Clin Pract Urol. 2007 Mar;4(3):155-60. doi: 10.1038/ncpuro0735.

Authors

Alberto A Antunes¹, Miguel Srougi, Rafael F Coelho, Geraldo de Campos Freire

Affiliation

¹ Division of Urology, University of São Paulo Medical School, São Paulo, SP, Brazil.

PMID: 17347660
DOI: 10.1038/ncpuro0735

Abstract

Botulinum toxin (BTX) is the most potent biological toxin used for the treatment of urologic conditions. During the last 3 years, the use of BTX has been extended to the treatment of symptomatic benign prostatic hyperplasia, however, the actual mechanism through which BTX can reduce prostate volume and infravesical resistance is not well understood. This article reviews the main effects of BTX in prostate tissues. A critical analysis of the outcomes of patients who were studied in clinical series that used this toxin to treat lower urinary tract symptoms related to benign prostatic hyperplasia is also presented.

Publication types

Review

MeSH terms

Botulinum Toxins, Type A / administration & dosage
Botulinum Toxins, Type A / therapeutic use*
Humans
Injections, Intralesional
Male
Neuromuscular Agents / administration & dosage
Neuromuscular Agents / therapeutic use*
Prostate
Prostatic Hyperplasia / complications*
Prostatic Hyperplasia / drug therapy
Treatment Outcome
Urinary Bladder, Overactive / drug therapy*
Urinary Bladder, Overactive / etiology
Urinary Bladder, Overactive / physiopathology
Urinary Retention / drug therapy*
Urinary Retention / etiology
Urinary Retention / physiopathology
Urodynamics

Substances

Neuromuscular Agents
Botulinum Toxins, Type A